Overview

A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the safety and clinical effects of 4 oral doses of TCH346 compared to placebo in patients with mild or mild to moderate stages of ALS.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis